Literature DB >> 31592085

Rapid Intrahepatic Progression of Hepatocellular Carcinoma after Transarterial Chemoembolization: A Case Report.

Tanveer H Siraj1, Asim Tameez Ud Din2, Farooq Mohyud Din Chaudhary1, Sultan Ahmad1, Khaleeq H Siddiqui3.   

Abstract

The prevalence of hepatocellular carcinoma (HCC) is increasing worldwide. Multiple strategies are available for its management including surgical removal, chemotherapeutic drugs, and ablative and chemoembolization procedures. Transarterial chemoembolization (TACE) is currently being used for the unresectable intrahepatic tumor with no vascular invasion or metastasis to other organs. The common adverse effects associated with this technique involve self-limiting fever, vomiting, and abdominal pain. Liver failure is reported in a few cases. In this report, we present a case of 37-year-old HCC patient who experienced rapid progression of tumor following TACE. Our patient came to the Gastroenterology & Hepatology Department, Nishtar Hospital, Multan, with signs concerning acute liver failure within a few months following TACE. On triphasic computed tomography (CT) scan, there was evidence of multiple new infiltrating lesions in both lobes of the liver and portal vein thrombosis, which were not present before TACE procedure. Hence, we made a diagnosis of acute, chronic liver disease due to the rapid intrahepatic progression of HCC. This is a rare side effect of TACE procedure and highlights the significance of proper counseling of the patients undergoing this intervention.
Copyright © 2019, Siraj et al.

Entities:  

Keywords:  acute on chronic liver failure; hepatocellular carcinoma; transarterial chemoembolization

Year:  2019        PMID: 31592085      PMCID: PMC6773453          DOI: 10.7759/cureus.5305

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  7 in total

1.  Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA-RH7777 hepatoma.

Authors:  Guang-Zhi Wang; Zhu-Ting Fang; Wei Zhang; Xu-Dong Qu; Sheng Qian; Rong Liu; Jian-Hua Wang
Journal:  Oncol Rep       Date:  2013-10-25       Impact factor: 3.906

Review 2.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Authors:  Ali Raza; Gagan K Sood
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance.

Authors:  Tae Wook Kang; Hyo Keun Lim; Min Woo Lee; Young-Sun Kim; Hyunchul Rhim; Won Jae Lee; Geum-Youn Gwak; Yong Han Paik; Ho Yeong Lim; Min Ji Kim
Journal:  Radiology       Date:  2015-02-25       Impact factor: 11.105

4.  Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma.

Authors:  Jin-Ping Lai; Andrew Conley; Beatrice S Knudsen; Maha Guindi
Journal:  Histopathology       Date:  2015-04-20       Impact factor: 5.087

5.  Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma After Combined Transarterial Chemoembolization and Radiofrequency Ablation.

Authors:  Kyoung Doo Song; Min Woo Lee; Hyunchul Rhim; Young-Sun Kim; Tae Wook Kang; Sung Wook Shin; Sung Ki Cho
Journal:  AJR Am J Roentgenol       Date:  2016-08-30       Impact factor: 3.959

6.  Adverse events following transarterial chemoembolization for hepatocellular carcinoma and factors predicting such events.

Authors:  Abbas Ali Tasneem; Zaigham Abbas; Nasir Hassan Luck; Syed Mujahid Hassan; Syed Muhammad Faiq
Journal:  J Pak Med Assoc       Date:  2013-02       Impact factor: 0.781

7.  Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Tae Wook Kang; Hyo Keun Lim; Dong Ik Cha
Journal:  Clin Mol Hepatol       Date:  2017-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.